Dr Oliver Zolman Collaborates with Brookstreet Equity Partners as Executive in Residence
Longevity: The Final Frontier
Dr Oliver Zolman Collaborates with Brookstreet Equity Partners of London as Executive in Residence
London, United Kingdom — 14 April 2026
Brookstreet Equity Partners LLP (“Brookstreet”), a London-based, award-winning investment manager, today confirmed that Dr Oliver Zolman has joined the firm as Executive in Residence (EIR), further strengthening its capabilities in longevity science and next-generation healthcare.
Dr Zolman is a medical doctor and researcher specialising in longevity medicine, biological ageing, and translational therapeutics. His work focuses on structured, multi-intervention approaches to ageing biology—integrating lifestyle optimisation, pharmacological strategies, and emerging therapies into cohesive, data-driven protocols designed to systematically improve human healthspan.
He is known for advancing a systems-based, biomarker-driven approach to ageing, where the body is treated as an interconnected network of measurable systems rather than isolated conditions. His work emphasises continuous measurement, iterative intervention, and protocol design aimed at optimising function across multiple biological pathways simultaneously.
Dr Zolman trained in regenerative and evidence-based medicine and has developed comprehensive frameworks to assess whole-body ageing. His work focuses on expanding the boundaries of what can be measured, tracked, and optimised in human biology through structured, data-driven approaches.
He is the architect of the “82 Organs Framework”, a system designed to assess and optimise function across the body at an organ-system level, and is connected to a global network of over 500 longevity-focused clinicians.
Dr Zolman has contributed to frontier initiatives in the field, including being recruited for involvement in the $101 million “XPRIZE Healthspan Prize”, and created “Project Blueprint” for Bryan Johnson (one of the most visible personalised longevity programmes globally) using his Longevity “Level 1-2-3” protocol, built on the principle that ageing can be quantified, monitored, and systematically improved through disciplined, multi-variable intervention.
His work and perspectives have been featured across major international media, including Netflix, BBC, Bloomberg, and The Times, reflecting the growing relevance of longevity science in mainstream healthcare and global discourse.
In his role as Executive in Residence, Dr Zolman will work closely with Brookstreet’s investment team to support the evaluation of longevity-focused opportunities, contribute domain expertise to due diligence and portfolio development, and help shape new strategies within this rapidly evolving sector.
Brookstreet is focused on high-velocity capital deployment across sectors including AI-enabled enterprise, energy transition, longevity, and dual-use technologies. The firm’s Executive in Residence programme brings together a select group of senior operators, founders, and domain experts to augment investment decision-making and accelerate value creation across its portfolio.
Omiros D. Sarikas, Managing Partner of Brookstreet, commented:
“Longevity is emerging as one of the most important investment frontiers of the next decade, combining advances in biology, data, AI, and clinical innovation. Dr Zolman operates at the intersection of these domains. His systems-based perspective and translational expertise are closely aligned with our approach to clinical longevity, prioritising scientific evidence over transient market dynamics.
Dr Zolman added:
“Ageing is no longer something we simply observe; it is increasingly something we can measure, model, and influence. The opportunity now lies in translating this understanding into structured, scalable systems. I am pleased to collaborate with Brookstreet, where frontier, clinically grounded science can be translated into real-world applications to extend healthspan, and, ultimately, lifespan.
***Ends***
About Brookstreet Equity Partners LLP
Brookstreet Equity Partners LLP (“Brookstreet”) is an award-winning investment platform established by a select group of shipping and principal-capital families. Its Brookstreet 2.0 thesis is built on optimising the efficiency frontier through diversification across stages, markets, regions, and instruments. The firm deploys hybrid growth capital, investing in AI-enabled innovations across digital transformation, energy transition, longevity, and dual-use technologies.
Headquartered in Mayfair, London, Brookstreet operates globally, partnering with founders and investors across the United States, Europe, MENA, and Asia.
About Dr Oliver Zolman
Dr Oliver Zolman is a medical doctor, researcher, and longevity specialist focused on biological ageing and translational therapeutic development. His work centres on designing multi-intervention, system-level protocols that integrate lifestyle, pharmacological, advanced therapies and emerging therapies to target fundamental biological ageing & healthspan biomarkers. He is known for his emphasis on measurement-driven medicine, where biological age and functional health are continuously tracked and improved through iterative intervention.
Dr Zolman has contributed to high-profile personalised longevity programmes, and is part of a growing global network of clinicians and researchers working to transition longevity from theoretical science into applied, clinical systems, including leading the training of other diverse clinicians. His work reflects a broader shift in medicine; from reactive treatment to proactive optimisation of human biology at scale.
